No articles found. Code: 200
No articles found. Code: 200
David Long, Director of Oncology, MSD UK and Professor Sir Mike Richards
To support the development of ideas and strategies to recover from the pandemic and deliver the long-term transformation in cancer services they so badly need, Public Policy Projects came together with biopharmaceutical company MSD and a panel of experts for a round table on what should be done. This short report, produced in partnership with MSD, is the result of those discussions.
Jo Churchill, Kruti Shotri, Rt Hon Stephen Dorrell
The way the NHS rose to the challenge of the pandemic shows what can be achieved when we pull together to deliver exceptional healthcare services for those who need them. However, the pandemic also had severe impacts on the delivery of other services. The number of new patients being recruited onto UK-based trials fell by 95 per cent in April 2020 compared with April 2019, the number of GP referrals fell by 60 per cent and there was an 85 per cent reduction in the number of completed pathways for cancer care. Perhaps more concerning is the 36 per cent of nurses and 17 per cent of GPs who said they were considering leaving the profession once the pandemic was under control according to the BMJ and Royal College of Nursing. In response to these concerns and building on the recently published government White Paper for healthcare reform, Public Policy Projects, in partnership with BMS, is launching a new report making bold recommendations for NHS England, the Department of Health and Social Care and service providers to support the restart of cancer services. This report, entitled Cancer services in the UK: Restarting the cancer pathway describes the big issues we need to tackle, not just to restore services, but to ‘build back better’ – using the talents of our healthcare services, research establishments and life sciences industry to deliver outstanding care. The impact of the Covid-19 could set the UK’s five-year cancer survival rate progress back by up to eight years. It is clear, therefore, that we need to bring the same determination and unity of purpose that we mustered to tackle the pandemic, to the restart cancer services.
Professor Karol Sikora, Professor Clare Turnbull, Professor Mark Lawler, Professor Geoff Bellingan, Matt Gibson, David Long
The outbreak of the Covid-19 pandemic has caused significant problems for those living with Cancer in the UK. At the very worst, it is estimated that thousands of people with cancer could die early due to suspensions in surgery while the NHS battles with the pandemic. It is imperative that screening services begin, and that the system rethinks its engagement strategy with the public to encourage at risk communities to get tested. Utilisation of the latest treatments and technologies are vital to enabling patients to access various cancer pathways. This session is an ideal opportunity to bring together leaders in the cancer sector, from policy makers and providers of treatments to leaders in industry. With national policies such as the NHS Long Term Plan needing to be revised with the fallout from Covid-19, there has never been a more important moment in the history of our nation than to be talking about renewing our focus on cancer survival rates.